Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures

Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures

Company Announcement


--  Worldwide net sales of Arzerra(R) in Q4 2013 totaled GBP 18.8 million
--  Full year 2013 net sales of Arzerra were GBP 74.9 million, an increase
     of 25% over 2012
--  Genmab royalty income is DKK 34 million for Q4 2013 and DKK 131 million
     for the year


COPENHAGEN, Denmark, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today that the Arzerra (ofatumumab) net
sales during the fourth quarter of 2013 were GBP 18.8 million
(approximately DKK 168 million). This figure consists of net sales in
the US of GBP 12.3 million and in the rest of the world of GBP 6.5
million. Under the terms of the collaboration with GlaxoSmithKline
(GSK), Genmab expects to receive a royalty payment of approximately DKK
34 million.

Full year 2013 net sales of Arzerra totaled GBP 74.9 million
(approximately DKK 658 million) worldwide, resulting in total royalty
income to Genmab of approximately DKK 131 million for the year.

During the first half of 2013, rest of world sales of Arzerra were
impacted by sales related to the supply of Arzerra for clinical trials
run by other companies. Sales were not positively impacted by clinical
trial material sales during the third and fourth quarters.

The conversion from GBP to DKK has been made using the Danish Central
Bank average rates for the respective quarters in 2013.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company
specializing in the creation and development of differentiated human
antibody therapeutics for the treatment of cancer. Founded in 1999, the
company's first marketed antibody, ofatumumab (Arzerra(R)), was
approved to treat chronic lymphocytic leukemia in patients who are
refractory to fludarabine and alemtuzumab after less than eight years
in development. Genmab's validated and next generation antibody
technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has
alliances with top tier pharmaceutical and biotechnology companies. For
more information visit www.genmab.com.

Contact:Rachel Curtis Gravesen, Senior Vice President, Investor
Relations & CommunicationsT: +45 33 44 77 20; M: +45 25 12 62 60; E:
[email protected]

This Company Announcement contains forward looking statements. The
words "believe", "expect", "anticipate", "intend" and "plan" and
similar expressions identify forward looking statements. Actual results
or performance may differ materially from any future results or
performance expressed or implied by such statements. The important
factors that could cause our actual results or performance to differ
materially include, among others, risks associated with pre-clinical
and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety
issues, uncertainties related to product manufacturing, the lack of
market acceptance of our products, our inability to manage growth, the
competitive environment in relation to our business area and markets,
our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary
rights, our relationships with affiliated entities, changes and
developments in technology which may render our products obsolete, and
other factors. For a further discussion of these risks, please refer to
the risk management sections in Genmab's most recent financial reports,
which are available on www.genmab.com. Genmab does not undertake any
obligation to update or revise forward looking statements in this
Company Announcement nor to confirm such statements in relation to
actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks:
Genmab(R); the Y-shaped Genmab logo(R); Genmab in combination with the
Y-shaped Genmab logo(TM); the DuoBody logo(TM); HuMax(R);
HuMax-CD20(R); DuoBody(R), HexaBody(TM) and UniBody(R). Arzerra(R) is a
registered trademark of GlaxoSmithKline.

Company Announcement no. 07CVR no. 2102 3884

Genmab A/SBredgade 34E1260 Copenhagen KDenmark

Attachments:

07 Arzerra Q4 2014 sales_uk_050214.pdf
 

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.